Chester County News and Community Website
PHOENIXVILLE, PA — PleoPharma, Inc. has closed a $36 million Series B financing round to accelerate development of PP-01, its lead investigational therapy for Cannabis Withdrawal in patients with Cannabis …
PleoPharma Secures $36 Million to Advance First Cannabis Withdrawal Treatment Read More PHOENIXVILLE, PA — PleoPharma, Inc. shared encouraging findings from its Phase 2b clinical trial of PP-01, a novel treatment for Cannabis Withdrawal Syndrome (CWS), during the 2025 annual meeting of …
PleoPharma Presents Promising Phase 2b Data on PP-01 for Cannabis Withdrawal Read More PHOENIXVILLE, PA — PleoPharma, Inc. has announced a significant intellectual property milestone with the issuance of its third U.S. patent, aimed at addressing sleep disturbances linked to cannabis withdrawal syndrome …
PleoPharma Secures Patent for Treating Sleep Disturbances in Cannabis Withdrawal Read More PHOENIXVILLE, PA — PleoPharma, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PP-01, the company’s lead investigational asset aimed at mitigating Cannabis …
FDA Grants Fast Track Designation to PleoPharma’s PP-01 for Cannabis Withdrawal Syndrome Read More PHOENIXVILLE, PA – PleoPharma, Inc. recently presented new data from its Phase 1b study on Cannabis Withdrawal Syndrome (CWS) at the American Academy of Addiction Psychiatry’s annual meeting in Naples, …
PleoPharma Showcases Promising Results in Study on Cannabis Withdrawal Syndrome Read More PHOENIXVILLE, PA — PleoPharma, Inc. has announced the issuance of two critical U.S. patents that bolster its efforts to treat cannabis withdrawal syndrome (CWS). These patents, U.S. Patent 11,197,846 and U.S. …
PleoPharma Secures Key Patents for Cannabis Withdrawal Treatment Read More